Results 101 to 110 of about 20,748 (167)

Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis. [PDF]

Ann Med
Tan S, Li Y, Cao Y, Sun W, Hui W.
europepmc   +1 more source

A Review of the Pathological and Molecular Diagnosis of Primary Myelofibrosis. [PDF]

Cancers (Basel)
Shao R, Ryder C, Wang L, Zhang H, Moscinski L, Martin M, Shebes M, Li JY, Song J.   +8 more
europepmc   +1 more source

Regression of Post-Essential Thrombocythaemia Myelofibrosis with Intermittent Hydroxyurea Therapy: A Case Report. [PDF]

J Clin Med
Manoharan A, Tang I.
europepmc   +1 more source

Quantitative assessment of innate myeloid cells in myelofibrosis: insights into myeloid and plasmacytoid dendritic cell depletion and disease progression. [PDF]

Ann Hematol
Silva NAC, Guirao FP, Barbosa MCR, Bernal DAO, Vassalli LC, Sandes AF.   +5 more
europepmc   +1 more source

Myelofibrosis.

Indian pediatrics, 1992
J, Chandra, S, Narayan, P, Kumar, R N, Ravi, P, Sahni, K B, Logani, D, Sharma   +6 more
openaire   +1 more source

Long-term real-world thrombotic and clinical outcomes in polycythemia vera - a hospital-based i2b2 cohort study. [PDF]

Ann Hematol
Neumark N, Jalowiec KA, Tichelli A, Porret N, Njue L, Vrotniakaite-Bajerciene K, Prince-Eladnani R, Angelillo-Scherrer A, Meyer SC, Rovó A.   +9 more
europepmc   +1 more source

Myeloid sarcoma transformed from myeloproliferative neoplasm: A case report and review of literature. [PDF]

World J Clin Oncol
Zhong SH, Lou J, Zhao AQ, Jin XL, Wei SM, Liang Y.   +5 more
europepmc   +1 more source

Fibrous Dysplasia Meets Intramuscular Myxoma: Mazabraud Syndrome-First Documented Case in Pakistan. [PDF]

Case Rep Med
Faisal A, Ali AY, Waqas H, Masood H, Hameed MS, Hadi NUHA, Omarzai RG.   +6 more
europepmc   +1 more source

Prognostic value of anemia plus thrombocytopenia in primary myelofibrosis. [PDF]

Leukemia
Barosi G, De Silvestri A, Gale RP, Rosti V.   +3 more
europepmc   +1 more source

Metformin Downregulates the STAT Pathway and Reduces Bone Marrow Fibrosis in Primary Myelofibrosis Patients: Final Results of the Phase II FIBROMET Trial. [PDF]

Hematol Oncol
Melo Campos P, Pagnano KBB, Niemann FS, Mancuso RI, Della Via FI, Congrains A, Coelho-Silva JL, Tinoco ÂC, Assis-Mendonça GR, Freitas LLL, Traina F, Saad STO.   +11 more
europepmc   +1 more source